Advertisement

Topics

BioAtla and Sinobioway Form JV to Develop CAB Cancer Drugs in China

01:44 EDT 17 Apr 2019 | ChinaBio Today

BioAtla a San Diego-Beijing biotech, out-licensed greater China rights for two of its products to Himalaya Therapeutics SEZC, a majority owned subsidiary of BioAtla. BioAtla develops Conditionally Active Biologic (CAB) oncology treatments. In exchange for a minority equity position in Himalaya, Beijing Sinobioway contributed all of its China rights to existing and future CAB candidates, which were part of its 2015 collaboration with BioAtla. Because China's regulatory system now accepts US data more readily, joint US-China development is more efficient, BioAtla said. More details....

Share this with colleagues:

Original Article: BioAtla and Sinobioway Form JV to Develop CAB Cancer Drugs in China

NEXT ARTICLE

More From BioPortfolio on "BioAtla and Sinobioway Form JV to Develop CAB Cancer Drugs in China"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...